Sapidyne
Private Company
Funding information not available
Overview
Sapidyne is a long-established, privately-held developer and manufacturer of specialized analytical biosensors. Its flagship KinExA® platform is a differentiated technology trusted for over 25 years to provide accurate, label-free measurements of binding interactions (Kd, kon, koff) and concentrations, particularly for ultra-high-affinity biologics like antibodies. The company operates on an instrument/consumables business model, selling the KinExA 4000 system, associated software, and reagents, while also offering contract research services. Its primary value proposition is unrivaled sensitivity and accuracy in measuring tight-binding interactions that challenge other technologies like Surface Plasmon Resonance (SPR).
Technology Platform
KinExA® (Kinetic Exclusion Assay) biosensor for label-free, solution-phase measurement of biomolecular binding affinity (Kd) and kinetics (kon, koff) from nanomolar to femtomolar sensitivity.
Opportunities
Risk Factors
Competitive Landscape
Sapidyne competes in the label-free biomolecular interaction analysis market, primarily against Surface Plasmon Resonance (SPR) platforms like Cytiva's Biacore and Bio-Layer Interferometry (BLI) platforms like Sartorius's Octet. Its competitive advantage is superior sensitivity for very tight-binding interactions, but it competes against technologies with higher throughput, broader adoption, and larger commercial ecosystems.